When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, ...

July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her ...

Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...